Drugs / BI 224436
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01276990 | Jan 2011 → Sep 2012 | HIV infectious disease | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 1 | NCT02183662 | Nov 2009 → Mar 2010 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 224436 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02183662 ↗ |
| Modality | Small molecule | — CHEMBL3259907 ↗ |
| Route | Oral | “following oral administration of repeated doses for 10 days within 8 dosing regimens” NCT01276990 ↗ |